| Tozasertib |
Aurora A, B and C |
First AKI in clinical use, simultaneous and successive treatment in CML and ALL |
| PHA-739358 (danusertib) |
Aurora A, B, C TrKA-a, Ret, FGR |
Phase II in prostate cancer, in combination use with sorafenib in HCC, phase II in multiple myeloma |
| CYC116 |
Selective effect on aurora A, B, inhibition of angiogenesis |
In combined use with ionizing radiation on ras-mutated colorectal adenocarcinoma, phase II in solid tumors |
| SNS-314 |
Pan-aurora kinase inhibitor |
Preclinical studies of cell lines and murine models of prostate, colon and breast cancers, phase I in solid tumors |
| AMG-900 |
Pan-aurora kinase inhibitor |
Preclinical studies of hematological and solid tumors |
| VE-465 |
Pan-aurora kinase inhibitor |
Antineoplastic activity in preclinical studies of HCC, ovarian cancer and hematologic malignancies |
| AS703569/R-763 |
Aurora A, B, C FLT1, FLT3, Abl, Akt, VEGFR3 |
Anticancer activity in cell culture in cell culture and murine xenograft models of hemopoietic and solid tumors |
| PF-03814735 |
Aurora A, B, C, FGFR1, FAK, TrKA, FLT1, MET |
Phase I for solid tumors |
| AT9283 |
Aurora A, B, Abl, JAK3, T3151 BCR-ABL, wild-type BCR-ABL |
Preclinical efficacy in hematologic malignancies |
| GSK1070916 |
Aurora B-INCEP, C-INCEP, SIK, FLT1, FGFR1, FLT4 |
In vivo efficacy in xenograft models, phase I in solid tumors |
| MLN8054 |
Selective inhibitor of AURKA |
Withdrawn from clinical use due to sever somnolence and central nervous system toxicity |
| MLN8237 |
Aurora A, B, T3151 BCR-ABL |
Seven ongoing phase II studies, one phase III recruiting patients |
